Antagonism of Metabotropic Glutamate Receptor Type 5 Attenuates L-dopa-induced Dyskinesia and Its Molecular and Neurochemical Correlates in a Rat Model of Parkinson's Disease.
From: Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Journal of neurochemistry
- Publish Date: Apr 2007
- ISSN: 0022-3042
- Volume: 101
- Issue: 2
- Pages: 483-97
- Medium: Print
- Language: English
- Citation (JAMA): Mela Flora, Marti Matteo, Dekundy Andrzej, et al. Antagonism of Metabotropic Glutamate Receptor Type 5 Attenuates L-dopa-induced Dyskinesia and Its Molecular and Neurochemical Correlates in a Rat Model of Parkinson's Disease.. J. Neurochem. Apr 2007;101:483-97
Abstract
Metabotropic glutamate receptor type 5 (mGluR5) modulates dopamine and glutamate neurotransmission at central synapses. In this study, we addressed the role of mGluR5 in l-DOPA-induced dyskinesia, a movement disorder that is due to abnormal activation of both dopamine and glutamate receptors in the basal ganglia. A selective and potent mGluR5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine, was tested for its ability to modulate molecular, behavioural and neurochemical correlates of dyskinesia in 6-hydroxydopamine-lesioned rats treated with l-DOPA. The compound significantly attenuated the induction of abnormal involuntary movements (AIMs) by chronic l-DOPA treatment at doses that did not interfere with the rat physiological motor activities. These effects were paralleled by an attenuation of molecular changes that are strongly associated with the dyskinesiogenic action of l-DOPA (i.e. up-regulation of prodynorphin mRNA in striatal neurons). Using in vivo microdialysis, we found a temporal correlation between the expression of l-DOPA-induced AIMs and an increased GABA outflow within the substantia nigra pars reticulata. When co-administered with l-DOPA, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine greatly attenuated both the increase in nigral GABA levels and the expression of AIMs. These data demonstrate that mGluR5 antagonism produces strong anti-dyskinetic effects in an animal model of Parkinson’s disease through central inhibition of the molecular and neurochemical underpinnings of l-DOPA-induced dyskinesia.
Mesh Headings (Keywords): Animals, Antiparkinson Agents, Brain, Disease Models, Animal, Drug Interactions, Dyskinesia, Drug-Induced, Excitatory Amino Acid Antagonists, Glutamic Acid, Levodopa, Microdialysis, Neural Inhibition, Parkinson Disease, Rats, Rats, Sprague-Dawley, Receptors, Metabotropic Glutamate, Substantia Nigra, Synaptic Transmission, gamma-Aminobutyric Acid
Check for Full Text / PubMed Unique Identifier (PMID): 17359492
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.